Bio-Rad reported last week that board member Philip Padou has died at the age of 72.
Padou joined Bio-Rad’s Board in 1980, and he was VP and CFO of Ozier Perry and Associates until his retirement in 1991.
David Schwartz, chairman of Bio-Rad’s board, said in a statement that Padou was “a dedicated and valuable member” of the board.
The company said it will begin seeking a replacement for Padou as soon as possible.
Invitrogen disclosed in an SEC filing last week that senior VP of commercial operations Ben Bulkley and finance and principal accounting officer John Radak will leave the company at the end of January.
Radak is taking on the role of CFO at Quidel, a developer of diagnostics for disease, at the beginning of February.
Bulkley will be replaced by current GM and VP of European operations Bernd Brust. Brust will be responsible for sales strategies, customer relations, and identifying avenues for customer growth.
Radak will be replaced by Kelli Richard, who has served as corporate controller at Invitrogen and as VP and controller at Gateway.
Former Sirna Therapeutics president and CEO Howard Robin has been hired to serve as president and chairman at biopharmaceutical company Nektar.
Robin was at Sirna for five years, where he oversaw the company's re-launch and its $1.1 billion acquisition by Merck. Robin also served as a VP and GM at Berlex Labs.
The Biotechnology Industry Organization announced that Sandra Dennis will be the organization’s new deputy general counsel for healthcare regulatory affairs.
Previously Dennis was a partner at Morgan, Lewis, & Bockius, LLP, where she focused on the FDA’s regulatory authority, legislative policies and corporate aspects of food, drug, and medical device law.